Hallmarks of 'BRCAness' in sporadic cancers (original) (raw)

• Wooster, R. & Weber, B. L. Breast and ovarian cancer. N. Engl. J. Med. 348, 2339–2347 (2003).
  Article CAS PubMed Google Scholar
• Venkitaraman, A. R. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 108, 171–182 (2002).
  Article CAS PubMed Google Scholar
• Tutt, A. & Ashworth, A. The relationship between the roles of BRCA genes in DNA repair and cancer predisposition. Trends Mol. Med. 8, 571–576 (2002).
  Article CAS PubMed Google Scholar
• Venkitaraman, A. R. Tracing the network connecting BRCA and fanconi anaemia proteins. Nature Rev. Cancer 4, 266–276 (2004).
  Article CAS Google Scholar
• D'andrea, A. D. & Grompe, M. The fanconi anaemia/BRCA pathway. Nature Rev. Cancer 3, 23–34 (2003).
  Article CAS Google Scholar
• Merajver, S. D. et al. Somatic mutations in the BRCA1 gene in sporadic ovarian tumours. Nature Genet. 9, 439–443 (1995).
  Article CAS PubMed Google Scholar
• Futreal, P. A. et al. BRCA1 mutations in primary breast and ovarian carcinomas. Science 266, 120–122 (1994).
  Article CAS PubMed Google Scholar
• Lancaster, J. M. et al. BRCA2 mutations in primary breast and ovarian cancers. Nature Genet. 13, 238–240 (1996).
  Article CAS PubMed Google Scholar
• Sorlie, T. et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl Acad. Sci. USA 98, 10869–10874 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Perou, C. M. et al. Molecular portraits of human breast tumours. Nature 406, 747–752 (2000).
  Article CAS PubMed Google Scholar
• Van 'T Veer, L. J. et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415, 530–536 (2002).
  Article CAS PubMed Google Scholar
• Sorlie, T. et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc. Natl Acad. Sci. USA 100, 8418–8423 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Smalley, M. & Ashworth, A. Stem cells and breast cancer: a field in transit. Nature Rev. Cancer 3, 832–844 (2003).
  Article CAS Google Scholar
• Foulkes, W. D. et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J. Natl Cancer Inst. 95, 1482–1485 (2003).
  Article CAS PubMed Google Scholar
• Hedenfalk, I. et al. Gene-expression profiles in hereditary breast cancer. N. Engl. J. Med. 344, 539–548 (2001).
  Article CAS PubMed Google Scholar
• Jazaeri, A. A. et al. Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. J. Natl Cancer Inst. 94, 990–1000 (2002).
  Article CAS PubMed Google Scholar
• Lakhani, S. R. et al. Profiling familial breast cancer. Nature Med. 7, 408–410 (2001).
  Article CAS PubMed Google Scholar
• Crook, T. et al. p53 mutation with frequent novel condons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours. Oncogene 17, 1681–1689 (1998).
  Article CAS PubMed Google Scholar
• Greenblatt, M. S., Chappuis, P. O., Bond, J. P., Hamel, N. & Foulkes, W. P. TP53 mutations in breast cancer associated with BRCA1 or BRCA2 germ-line mutations: Distinctive spectrum and structural distribution. Cancer Res. 61, 4092–4097 (2001).
  CAS PubMed Google Scholar
• Bischoff, J. R. & Plowman, G. D. The aurora/ipl1p kinase family: regulators of chromosome segregation and cytokinesis. Trends Cell Biol. 9, 454–459 (1999).
  Article CAS PubMed Google Scholar
• Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57–70 (2000).
  Article CAS PubMed Google Scholar
• Lakhani, S. et al. Basal markers and estogen receptor status are powerful predictors of germline BRCA1 mutations. Proc. Am. Assoc. Cancer Res. abstract 5593 (2004).
• Tirkkonen, M. et al. Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. Cancer Res. 57, 1222–1227 (1997).
  CAS PubMed Google Scholar
• Wessels, L. F. et al. Molecular classification of breast carcinomas by comparative genomic hybridization: a specific somatic genetic profile for brca1 tumors. Cancer Res. 62, 7110–7117 (2002).
  CAS PubMed Google Scholar
• Jones, P. A. & Baylin, S. B. The fundamental role of epigenetic events in cancer. Nature Rev. Genet. 3, 415–428 (2002).
  Article CAS PubMed Google Scholar
• Esteller, M. et al. Promoter hypermethylation and brca1 inactivation in sporadic breast and ovarian tumors. J. Natl Cancer Inst. 92, 564–569 (2000).
  Article CAS PubMed Google Scholar
• Rice, J. C. et al. Methylation of the BRCA1 promoter is associated with decreased BRCA1 mRNA levels in clinical breast cancer specimens. Carcinogenesis 21, 1761–1765 (2000).
  Article CAS PubMed Google Scholar
• Catteau, A. et al. Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics. Oncogene 18, 1957–1965 (1999).
  Article CAS PubMed Google Scholar
• Geisler, J. P. et al. Frequency of BRCA1 dysfunction in ovarian cancer. J. Natl Cancer Inst. 94, 61–67 (2002).
  Article CAS PubMed Google Scholar
• Baldwin, R. L. et al. BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study. Cancer Res. 60, 5329–5333 (2000).
  CAS PubMed Google Scholar
• Chan, K. Y. et al. Epigenetic factors controlling the BRCA1 and BRCA2 genes in sporadic ovarian cancer. Cancer Res. 62, 4151–4156 (2002).
  CAS PubMed Google Scholar
• Staff, S. et al. Haplo-insufficiency of BRCA1 in sporadic breast cancer. Cancer Res. 63, 4978–4983 (2003).
  CAS PubMed Google Scholar
• Bianco, T. et al. Tumour-specific distribution of BRCA1 promoter region methylation supports a pathogenetic role in breast and ovarian cancer. Carcinogenesis 21, 147–151 (2000).
  Article CAS PubMed Google Scholar
• Marsit, C. J. et al. Inactivation of the fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival. Oncogene 23, 1000–1004 (2004).
  Article CAS PubMed Google Scholar
• Narayan, G. et al. Promoter hypermethylation of FANCF: disruption of fanconi anemia-BRCA pathway in cervical cancer. Cancer Res. 64, 2994–2997 (2004).
  Article CAS PubMed Google Scholar
• Futreal, P. A. et al. A census of human cancer genes. Nature Rev. Cancer 4, 177–183 (2004).
  Article CAS Google Scholar
• Baylin, S. & Bestor, T. H. Altered methylation patterns in cancer cell genomes: cause or consequence? Cancer Cell 1, 299–305 (2002).
  Article CAS PubMed Google Scholar
• Grushko, T. A. et al. Myc is amplified in BRCA1-associated breast cancers. Clin. Cancer Res. 10, 499–507 (2004).
  Article CAS PubMed Google Scholar
• Magdinier, F. et al. Down-regulation of BRCA1 in human sporadic breast cancer; analysis of DNA methylation patterns of the putative promoter region. Oncogene 17, 3169–3176 (1998).
  Article CAS PubMed Google Scholar
• Miller, B. J. et al. Pooled analysis of loss of heterozygosity in breast cancer: a genome scan provides comparative evidence for multiple tumor suppressors and identifies novel candidate regions. Am. J. Hum. Genet. 73, 748–767 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Beckmann, M. W. et al. Clinical impact of detection of loss of heterozygosity of BRCA1 and BRCA2 markers in sporadic breast cancer. Br. J. Cancer 73, 1220–1226 (1996).
  Article CAS PubMed PubMed Central Google Scholar
• Santarosa, M. & Ashworth, A. Haploinsufficiency for tumour suppressor genes: when you don't need to go all the way. Biochim. Biophys. Acta 1654, 105–122 (2004).
  CAS PubMed Google Scholar
• Baldeyron, C. et al. A single mutated BRCA1 allele leads to impaired fidelity of double strand break end-joining. Oncogene 21, 1401–1410 (2002).
  Article CAS PubMed Google Scholar
• Taniguchi, T. et al. Disruption of the fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nature Med. 9, 568–574 (2003).
  Article CAS PubMed Google Scholar
• Wei, M. et al. FANCF promoter is methylated in human sporadic breast cancers. Proc. Am. Soc. Hum. Genet. abstract 471 (2003).
• Van Der Heijden, M. S. et al. Fanconi anemia gene mutations in young-onset pancreatic cancer. Cancer Res. 63, 2585–2588 (2003).
  CAS PubMed Google Scholar
• Collins, N. et al. Absence of methylation of CpG dinucleotides within the promoter of the breast cancer susceptibility gene BRCA2 in normal tissues and in breast and ovarian cancers. Br. J. Cancer 76, 1150–1156 (1997).
  Article CAS PubMed PubMed Central Google Scholar
• Hilton, J. L. et al. Inactivation of BRCA1 and BRCA2 in ovarian cancer. J. Natl Cancer Inst. 94, 1396–1406 (2002).
  Article CAS PubMed Google Scholar
• Hughes-Davies, L. et al. EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. Cell 115, 523–535 (2003).
  Article CAS PubMed Google Scholar
• Stoppa-Lyonnet, D. et al. Familial invasive breast cancers: worse outcome related to brca1 mutations. J. Clin. Oncol. 18, 4053–4059 (2000).
  Article CAS PubMed Google Scholar
• Verhoog, L. C. et al. Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet 351, 316–321 (1998).
  Article CAS PubMed Google Scholar
• Robson, M. E. et al. A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res. 6, R8–R17 (2004).
  Article CAS PubMed Google Scholar
• Foulkes, W. D. et al. Disruption of the expected positive correlation between breast tumor size and lymph node status in BRCA1-related breast carcinoma. Cancer 98, 1569–1577 (2003).
  Article PubMed Google Scholar
• Howlett, N. G. et al. Biallelic inactivation of BRCA2 in fanconi anemia. Science 297, 606–609 (2002).
  Article CAS PubMed Google Scholar
• Kraakman-Van Der Zwet, M. et al. BRCA2 (xrcc11) deficiency results in radioresistant DNA synthesis and a higher frequency of spontaneous deletions. Mol. Cell. Biol. 22, 669–679 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Bhattacharyya, A. et al. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of RAD51 and survival following treatment with the DNA cross-linking agent cisplatin. J. Biol. Chem. 275, 23899–23903 (2000).
  Article CAS PubMed Google Scholar
• Moynahan, M. E. et al. Homology-directed dna repair, mitomycin-C resistance, and chromosome stability is restored with correction of a BRCA1 mutation. Cancer Res. 61, 4842–4850 (2001).
  CAS PubMed Google Scholar
• Tassone, P. et al. BRCA1 expression modulates chemosensitivity of BRCA1-defective hcc1937 human breast cancer cells. Br. J. Cancer 88, 1285–1291 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Quinn, J. E. et al. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res. 63, 6221–6228 (2003).
  CAS PubMed Google Scholar
• Fedier, A. et al. The effect of loss of BRCA1 on the sensitivity to anticancer agents in p53-deficient cells. Int. J. Oncol. 22, 1169–1173 (2003).
  CAS PubMed Google Scholar
• Couzin, J. Choices—and uncertainties — for women with BRCA mutations. Science 302, 592 (2003).
  Article CAS PubMed Google Scholar
• Meetei, A. R. et al. A novel ubiquitin ligase is deficient in fanconi anemia. Nature Genet. 35, 165–170 (2003).
  Article CAS PubMed Google Scholar
• Garcia-Higuera, I. et al. Interaction of the fanconi anemia proteins and BRCA1 in a common pathway. Mol. Cell 7, 249–262 (2001).
  Article CAS PubMed Google Scholar
• Hussain, S. et al. Direct interaction of FANCD2 with BRCA2 in DNA damage response pathways. Hum. Mol. Genet. 13, 1241–1248 (2004).
  Article CAS PubMed Google Scholar
• Rothfuss, A. & Grompe, M. Repair kinetics of genomic interstrand DNA cross-links: evidence for DNA double-strand break-dependent activation of the fanconi anemia/BRCA pathway. Mol. Cell. Biol. 24, 123–134 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Mchugh, P. J. et al. Repair of DNA interstrand crosslinks: molecular mechanisms and clinical relevance. Lancet Oncol. 2, 483–490 (2001).
  Article CAS PubMed Google Scholar
• Breast Cancer and Linkage Consortium. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet 349, 1505–1510 (1997).
• Lakhani, S. R. et al. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J. Clin. Oncol. 20, 2310–2318 (2002).
  Article CAS PubMed Google Scholar
• Palacios, J. et al. Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers. Clin. Cancer Res. 9, 3606–3614 (2003).
  CAS PubMed Google Scholar
• Lakhani, S. R. et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J. Natl Cancer Inst. 90, 1138–1145 (1998).
  Article CAS PubMed Google Scholar
• Foster, K. A. et al. Somatic and germline mutations of the BRCA2 gene in sporadic ovarian cancer. Cancer Res. 56, 3622–3625 (1996).
  CAS PubMed Google Scholar